, a biotech company in 无码群交’s Helix 51 biomedical incubator, was awarded an Illinois Innovation Voucher grant for $75,000 for its collaboration with 无码群交 (RFU). UP Oncolytics is developing a novel treatment for Glioblastoma Multiforme (GBM), the most aggressive form of malignant brain cancer.

GBM is the leading cause of cancer-related deaths among men under 40 in the United States. Approximately 13,000 new cases of GBM are diagnosed annually. The median survival time for patients is about 14 months, and the five-year survival rate remains at only 7.1%. No new therapeutic agents have received approval in the U.S. in the past 20 years.

Established by the Illinois Department of Commerce and Economic Opportunity (DCEO) and administered by the Illinois Science & Technology Coalition (ISTC) to support collaborations between Illinois universities and small businesses, the grant will help UP Oncolytics complete Investigational New Drug (IND) experiments at RFU’s research labs for its initial candidate to treat GBM.

“ISTC and Illinois DCEO are providing important support to an exciting early-stage cancer biotech company, which promises new therapeutic treatment options,” said Joseph DiMario, PhD, RFU’s executive vice president for research. “We are proud to be assisting UP Oncolytics in the development of this novel therapy for this terrible fatal disease.”

UP Oncolytics completed an exclusive license agreement for this novel therapy based on an oncolytic virus from Advocate Health in 2025. It was awarded an NIH SBIR Fast Track grant for this technology and FDA Orphan Drug designation for malignant gliomas, a broader group of brain cancers including GBM. The company expanded its oncology expertise with new board members Dr. Gary Gordon, a Johns Hopkins-trained oncologist and former vice president of clinical oncology at AbbVie, and Michael Rosen, a former oncology biotech CEO and executive with Pfizer, Bristol-Myers Squibb and Searle.